Respiratory DisorderVISION-MDNCT04763746
The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of Care - Multi-site Development
An observational study of Respiratory Disorder and Diabetes, run by Xim Limited at 1 site in United Kingdom.
Trial summary
AIM: To advance the development and accuracy of the Lifelight® app for the measurement of vital signs, therefore developing a non-invasive and easy-to-perform means of measuring vital signs which can be implemented across a wide range of settings, both within hospitals and out in the community. Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- Respiratory Disorder, Diabetes, Cardiovascular Diseases
- What is being tested?
- Lifelight Data Collect Sub-protocol 1, Lifelight Data Collect Sub-protocol 2 and Lifelight Data Collect Sub-protocol 3
- Type of treatment
- Pill or oral medicine, Medical device
- How many people
- 1,869 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jun 2021to 1 Apr 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Inpatients, outpatients, staff and healthy participants - adults only (16+)
Who may be able to join
- 16 years old or above
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Portsmouth Hospitals NHS Trust
Portsmouth, England, PO6 3LY
About this study
Official title: The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of - Multi-site Development: The VISION-MD Study
AIM: To advance the development and accuracy of the Lifelight® app for the measurement of vital signs, therefore developing a non-invasive and easy-to-perform means of measuring vital signs which can be implemented across a wide range of settings, both within hospitals and out in the community.
METHOD: Lifelight® is a computer program ("app") for measuring vital signs which can be used on smart devices that contain a camera. It is able to measure all of the vital signs by measuring very small changes in skin colour that occur each time the heart beats. This means that it does not need to touch the patient. The investigators believe this could be an effective way of measuring vital signs, especially during the COVID-19 pandemic when prevention of cross-contamination between patients is essential. Patients are also likely to be reassured by a contactless approach. The app uses data from looking at a person's face to calculate the vital signs. This is possible because there are tiny changes in facial skin that occur each time the heart beats.
Read more
The investigators believe Lifelight® could be an effective way of measuring vital signs. The app is still under development, which means that it is still "learning" the best match between the information it collects from the face and the values of vital signs measured using the standard equipment. The app should become more accurate in calculating the vital signs as it sees more and more information from patients.
So far, the app has seen data from inpatients, outpatients, patients attending GP surgeries and healthy people. This has improved its accuracy in measuring vital signs. However, the app needs to see more information so that it can be sufficiently accurate for specific clinical applications such as long-term monitoring of hypertension. To do this, it particularly needs to see information from people with abnormal blood pressures and blood oxygen levels. In order to capture the full range of observations, the app will need to be trialled with some of the most critically ill patients - some of these will not have capacity to consent to participation in the study. It also needs to see more data from people with different skin tones so the investigators can be sure it is accurate for all patients.
To do this, the investigators will recruit people who are attending one of two hospitals, either as an inpatient, an outpatient, a friend/relative of a patient, or a member of hospital staff. The exact number will depend on how quickly the app "learns" and how many of the vital signs are outside of the normal range. The investigators will take the participant's vital signs using standard clinical equipment whilst recording a video of their face. The investigators will use most of these measurements and video to teach the app how to become more accurate at measuring vital signs. The investigators will keep the remaining data separate and use it to test how accurate the app is. All of the data will be kept securely.
The investigators will also collect feedback from participants and healthcare staff on their experiences using the app and information that allows us to assess whether there are any savings to the healthcare economy through use of this technology.
Read the detailed description
Following informed consent, the study staff member will complete a very brief set of demographic and medical history questions, limited to the presence or absence of medical problems and treatment for them.
Participants with capacity to consent will be recruited into either Sub-protocol 1, 2 or 3 on the basis of which vital signs are expected to be abnormal. Participants who lack capacity to consent to take part in the study will be recruited into Sub-protocol 4.
- Sub-protocol 1 participants will have blood pressure, oxygen saturation and heart rate measured.
- Sub-protocol 2 participants will have respiratory rate and oxygen saturation measured.
- Sub-protocol 3 participants will have oxygen saturation measured.
- Sub-protocol 4 participants will have blood pressure, heart rate, respiratory rate and oxygen saturation measured.
Participants may also be recruited to a sub-protocol on the basis of their skin tone. This is because there are targets within Sub-protocols 1, 2 and 3 related to skin tone.
Not all vital signs are collected in all participants to focus study nurse attention on fewer tasks and to avoid collection of data that is not subsequently used to meet the study objectives. This approach should help to keep all aspects of data collection as high quality as possible and is consistent with the GDPR requirement of data minimisation.
For all Sub-protocol 1, 2, 3 and 4 participants, the study team will complete a set of pre-measurement observation questions. Background luminosity will be measured using a handheld lux meter. The staff member will then prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using the Data Collect app. Best efforts will be made to adhere to the Lifelight® measurement conditions listed in Appendix B. These measurements and video capture will be repeated once more in the case of Sub-protocols 2 and 3, and twice more in the case of Sub-protocols 1 and 4. Once measurements are concluded, the study staff member will complete the post-measurement observation questions. In all cases, the cleaning protocol outlined in Appendix D will be adhered to after each study session.
A selection of Sub-protocol 1, 2 and 3 participants will be asked to complete a questionnaire related to vital sign monitoring and their preference of Lifelight® or other technologies for measuring vital signs.
- Conditions
- Respiratory Disorder, Diabetes, Cardiovascular Diseases, Critical Care, Trauma and Emergency Care, Primary Care
- Being tested
- Lifelight Data Collect Sub-protocol 1, Lifelight Data Collect Sub-protocol 2, Lifelight Data Collect Sub-protocol 3, Lifelight Data Collect Sub-protocol 4
- Keywords
- vital signs, innovation, lifelight, blood pressure, oxygen saturation, contactless, rPPG
- Medical subject headings
- Respiration Disorders, Diabetes Mellitus, Cardiovascular Diseases, Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lifelight Data Collect Sub-protocol 1Device
Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.
Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.
This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets.
Lifelight Data Collect Sub-protocol 2Device
Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.
Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.
This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets.
Lifelight Data Collect Sub-protocol 3Device
The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.
This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets.
Lifelight Data Collect Sub-protocol 4Device
Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.
Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.
This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets.
| Study group | Role | What they receive |
|---|---|---|
| Sub-protocol 1 | Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure.
Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. Receives: Device: Lifelight Data Collect Sub-protocol 1 | |
| Sub-protocol 2 | Respiratory rate and oxygen saturation measured from any participant.
Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. Receives: Device: Lifelight Data Collect Sub-protocol 2 | |
| Sub-protocol 3 | Oxygen saturation measured from participants expected to have low oxygen saturation.
Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. Receives: Device: Lifelight Data Collect Sub-protocol 3 | |
| Sub-protocol 4 | Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity.
Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. Receives: Device: Lifelight Data Collect Sub-protocol 4 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Train Lifelight algorithms across more extensive clinical ranges, including patients with an blood oxygen saturation of <92%, to reach closer to a performance target of 4% maximum error tolerance.
Measured: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a systolic blood pressure of <90 or >180 mmHg, to progress towards British Hypertension Society Grade C and a standard deviation performance target of <8mmHg.
Measured: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a diastolic blood pressure of >110 mmHg, to improve Lifelight's British Hypertension Society Grade B grading and standard deviation performance target of <8mmHg
Measured: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a pulse of <40bpm or >120bpm, to reach closer to the indicative performance target of an RMSE of 3bpm or less.
Measured: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a respiration rate of >25 rpm, to reach closer to the indicative performance target of a 5 breath per minute maximum error tolerance.
Measured: 12 months
Train Lifelight algorithms on a more diverse population, including patients with Fitzpatrick scale 1, 4, 5 and 6 skin tones.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2021
- Study start1 Jun 2021
- Primary completion14 Apr 2022
- Study completion1 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Respiratory DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,869 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xim Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Laura Wiffen, Principal investigator, Portsmouth Hospitals NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04763746
- Sponsor's protocol ID
- IRAS: 289242
- Acronym
- VISION-MD
- Status last verified
- Jan 2023
- First submitted
- 8 Feb 2021
- Last updated
- 26 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kiddle A, Barham H, Wegerif S, Petronzio C. Dynamic Region of Interest Selection in Remote Photoplethysmography: Proof-of-Concept Study. JMIR Form Res. 2023 Mar 30;7:e44575. doi: 10.2196/44575.
PubMed 36995742Wiffen L, Brown T, Brogaard Maczka A, Kapoor M, Pearce L, Chauhan M, Chauhan AJ, Saxena M; Lifelight Trials Group. Measurement of Vital Signs by Lifelight Software in Comparison to Standard of Care Multisite Development (VISION-MD): Protocol for an Observational Study. JMIR Res Protoc. 2023 Jan 11;12:e41533. doi: 10.2196/41533.
PubMed 36630158
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of - Multi-site Development: The VISION-MD Study
- ClinicalTrials.gov ID
- NCT04763746
- Acronym / sponsor ID
- VISION-MD / IRAS: 289242
- Conditions
- Respiratory Disorder, Diabetes, Cardiovascular Diseases, Critical Care, Trauma and Emergency Care, Primary Care
- Keywords
- vital signs, innovation, lifelight, blood pressure, oxygen saturation, contactless, rPPG
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,869 participants (actual)
- Lead sponsor
- Xim LimitedIndustry (pharma, biotech, devices)
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 14 Apr 2022 (actual)
- Study completion
- 1 Apr 2023 (actual)
- First posted
- 21 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AIM: To advance the development and accuracy of the Lifelight® app for the measurement of vital signs, therefore developing a non-invasive and easy-to-perform means of measuring vital signs which can be implemented across a wide range of settings, both within hospitals and out in the community.
METHOD: Lifelight® is a computer program ("app") for measuring vital signs which can be used on smart devices that contain a camera. It is able to measure all of the vital signs by measuring very small changes in skin colour that occur each time the heart beats. This means that it does not need to touch the patient. The investigators believe this could be an effective way of measuring vital signs, especially during the COVID-19 pandemic when prevention of cross-contamination between patients is essential. Patients are also likely to be reassured by a contactless approach. The app uses data from looking at a person's face to calculate the vital signs. This is possible because there are tiny changes in facial skin that occur each time the heart beats.
The investigators believe Lifelight® could be an effective way of measuring vital signs. The app is still under development, which means that it is still "learning" the best match between the information it collects from the face and the values of vital signs measured using the standard equipment. The app should become more accurate in calculating the vital signs as it sees more and more information from patients.
So far, the app has seen data from inpatients, outpatients, patients attending GP surgeries and healthy people. This has improved its accuracy in measuring vital signs. However, the app needs to see more information so that it can be sufficiently accurate for specific clinical applications such as long-term monitoring of hypertension. To do this, it particularly needs to see information from people with abnormal blood pressures and blood oxygen levels. In order to capture the full range of observations, the app will need to be trialled with some of the most critically ill patients - some of these will not have capacity to consent to participation in the study. It also needs to see more data from people with different skin tones so the investigators can be sure it is accurate for all patients.
To do this, the investigators will recruit people who are attending one of two hospitals, either as an inpatient, an outpatient, a friend/relative of a patient, or a member of hospital staff. The exact number will depend on how quickly the app "learns" and how many of the vital signs are outside of the normal range. The investigators will take the participant's vital signs using standard clinical equipment whilst recording a video of their face. The investigators will use most of these measurements and video to teach the app how to become more accurate at measuring vital signs. The investigators will keep the remaining data separate and use it to test how accurate the app is. All of the data will be kept securely.
The investigators will also collect feedback from participants and healthcare staff on their experiences using the app and information that allows us to assess whether there are any savings to the healthcare economy through use of this technology.
Detailed description
Following informed consent, the study staff member will complete a very brief set of demographic and medical history questions, limited to the presence or absence of medical problems and treatment for them.
Participants with capacity to consent will be recruited into either Sub-protocol 1, 2 or 3 on the basis of which vital signs are expected to be abnormal. Participants who lack capacity to consent to take part in the study will be recruited into Sub-protocol 4.
- Sub-protocol 1 participants will have blood pressure, oxygen saturation and heart rate measured.
- Sub-protocol 2 participants will have respiratory rate and oxygen saturation measured.
- Sub-protocol 3 participants will have oxygen saturation measured.
- Sub-protocol 4 participants will have blood pressure, heart rate, respiratory rate and oxygen saturation measured.
Participants may also be recruited to a sub-protocol on the basis of their skin tone. This is because there are targets within Sub-protocols 1, 2 and 3 related to skin tone.
Not all vital signs are collected in all participants to focus study nurse attention on fewer tasks and to avoid collection of data that is not subsequently used to meet the study objectives. This approach should help to keep all aspects of data collection as high quality as possible and is consistent with the GDPR requirement of data minimisation.
For all Sub-protocol 1, 2, 3 and 4 participants, the study team will complete a set of pre-measurement observation questions. Background luminosity will be measured using a handheld lux meter. The staff member will then prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using the Data Collect app. Best efforts will be made to adhere to the Lifelight® measurement conditions listed in Appendix B. These measurements and video capture will be repeated once more in the case of Sub-protocols 2 and 3, and twice more in the case of Sub-protocols 1 and 4. Once measurements are concluded, the study staff member will complete the post-measurement observation questions. In all cases, the cleaning protocol outlined in Appendix D will be adhered to after each study session.
A selection of Sub-protocol 1, 2 and 3 participants will be asked to complete a questionnaire related to vital sign monitoring and their preference of Lifelight® or other technologies for measuring vital signs.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Sub-protocol 1 | – | Device: Lifelight Data Collect Sub-protocol 1Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure. Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. |
| Sub-protocol 2 | – | Device: Lifelight Data Collect Sub-protocol 2Respiratory rate and oxygen saturation measured from any participant. Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. |
| Sub-protocol 3 | – | Device: Lifelight Data Collect Sub-protocol 3Oxygen saturation measured from participants expected to have low oxygen saturation. Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. |
| Sub-protocol 4 | – | Device: Lifelight Data Collect Sub-protocol 4Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity. Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Inpatients, outpatients, staff and healthy participants - adults only (16+)
Key inclusion criteria (1 listed)
- 16 years old or above
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lifelight Data Collect Sub-protocol 1Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading. Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading. This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets. | Device | Sub-protocol 1 |
| Lifelight Data Collect Sub-protocol 2Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading. Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting. This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets. | Device | Sub-protocol 2 |
| Lifelight Data Collect Sub-protocol 3The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period. This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets. | Device | Sub-protocol 3 |
| Lifelight Data Collect Sub-protocol 4Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting. Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading. This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets. | Device | Sub-protocol 4 |
Primary outcome
Train Lifelight algorithms across more extensive clinical ranges, including patients with an blood oxygen saturation of <92%, to reach closer to a performance target of 4% maximum error tolerance.
Time frame: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a systolic blood pressure of <90 or >180 mmHg, to progress towards British Hypertension Society Grade C and a standard deviation performance target of <8mmHg.
Time frame: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a diastolic blood pressure of >110 mmHg, to improve Lifelight's British Hypertension Society Grade B grading and standard deviation performance target of <8mmHg
Time frame: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a pulse of <40bpm or >120bpm, to reach closer to the indicative performance target of an RMSE of 3bpm or less.
Time frame: 12 months
Train Lifelight algorithms across more extensive clinical ranges, including patients with a respiration rate of >25 rpm, to reach closer to the indicative performance target of a 5 breath per minute maximum error tolerance.
Time frame: 12 months
Train Lifelight algorithms on a more diverse population, including patients with Fitzpatrick scale 1, 4, 5 and 6 skin tones.
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2024.
- Derived from this study: PubMed 36995742Kiddle A, Barham H, Wegerif S, Petronzio C. Dynamic Region of Interest Selection in Remote Photoplethysmography: Proof-of-Concept Study. JMIR Form Res. 2023 Mar 30;7:e44575. doi: 10.2196/44575.
- Derived from this study: PubMed 36630158Wiffen L, Brown T, Brogaard Maczka A, Kapoor M, Pearce L, Chauhan M, Chauhan AJ, Saxena M; Lifelight Trials Group. Measurement of Vital Signs by Lifelight Software in Comparison to Standard of Care Multisite Development (VISION-MD): Protocol for an Observational Study. JMIR Res Protoc. 2023 Jan 11;12:e41533. doi: 10.2196/41533.
- Individual participant dataSharing planned: No
Related trials for Respiratory Disorder
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laura Wiffen principal investigator
Portsmouth Hospitals NHS Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Disorder and Diabetes, run by Xim Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Train Lifelight algorithms across more extensive clinical ranges, including patients with an blood oxygen saturation of <92%, to reach closer to a performance target of 4% maximum error tolerance. (time frame: 12 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04763746, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2024; AzTrials last refreshed its copy on 8 Nov 2026.